Merck Sharp & Dohme Corp. has disclosed adenosine A2A (ADORA2A) and/or A2B (ADORA2B) receptor antagonists reported to be useful for the treatment of cancer.
Pacira Cryotech Inc. reported the filing of a patent for a hand-held cryogenic treatment system with a probe configured to apply a cryogenic therapy to one or more nerves, such as the nerves of the stellate ganglion and autonomic tissue peripheral to the stellate ganglion.
Sichuan Haisco Pharmaceutical Co. Ltd. has described N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of cancer.
Novartis AG has synthesized glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, hypertension, stroke, hyperglycemia, dyslipidemia, nonalcoholic steatohepatitis and diabetic nephropathy, among others.
Neurochase Ltd. filed a patent for a septum-sealed transcutaneous, fluid-transferring device through which repeated access for the removal or delivery of fluid to the central nervous system (CNS) can be gained.
Etern Biopharma (Shanghai) Co. Ltd. has described bicyclic heteroaryl compounds acting as transcriptional coactivator YAP1 and/or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, fibrosis and cardiovascular disorders.
Vertex Pharmaceuticals Inc. has divulged cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
RSS
